



AMGEN
UNLOCKING
THE POTENTIAL
OF BIOLOGY
FOR PATIENTS



OUR MISSION

To serve patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.





OUR ASPIRATION

We aspire to be the best human therapeutics company. We will live the Amgen Values and use science and innovation to dramatically improve people's lives.

AMGEN VALUES

- Be science-based
- Compete intensely and win
- Create value for patients, staff and stockholders
- Be ethical
- Trust and respect each other
- Ensure quality
- Work in teams
- Collaborate, communicate and be accountable

DAWN OF THE BIO-CENTURY


Never before have we been in a better position to understand and combat human disease. Biotechnology has evolved rapidly in the past three decades. And yet we remain an industry in its infancy, which means we have only begun to realize the full potential of biotechnology and how it can benefit human health.

Many of the past century's breakthrough innovations were in the areas of physics and information technology. We believe we have entered an exciting new era—the Bio-Century—where there is great potential for new discoveries as we gain a deeper understanding of human biology and biotechnology.

Major advances in DNA sequencing and gene therapy are leading to exciting opportunities in discovery research. We also see growing global demand for biologic medicines on the horizon due to factors ranging from greater access to healthcare to aging populations to new kinds of cancer treatments. And investments are being made based on extensive knowledge of biologics manufacturing to improve existing processes and technologies to help further optimize the outcomes we deliver to patients.

Amgen is well positioned to break new ground in our industry—at the dawn of the Bio-Century—and serve more patients with our therapeutics worldwide.



A photograph of two scientists in a laboratory setting. In the foreground, an older man with grey hair and safety glasses is wearing a white lab coat and green gloves, working on a piece of equipment. In the background, a younger man with dark hair and safety glasses is also wearing a white lab coat and is looking down at the same equipment. The equipment is a large, complex machine with various components, including a large circular dial on the right side. The text "Never before have we been in a better position to understand and combat human disease." is overlaid in white, italicized font across the center of the image. The entire image has a warm, yellowish-orange tint.


*Never before have we been in
a better position to understand
and combat human disease.*



WHAT WE DO

PIONEERING MEDICINES

We have a presence in approximately 100 countries worldwide and have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Our medicines typically address diseases for which the number of effective treatment options is limited, or they are medicines that provide a viable option to what is otherwise available.



INNOVATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease, Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS MANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

For more information about our world-class manufacturing, visit biotechnologybyamgen.com.



OUR HERITAGE

CULTURE OF SCIENCE AND INNOVATION

The story of Amgen began more than three decades ago with a simple idea—that emerging research in genetics could lead to very exciting opportunities if the right scientists could be assembled and given the appropriate resources. Amgen has since grown to be the world's largest independent biotechnology company, launching some of the biotechnology industry's first blockbuster therapies, and subsequently changing the course of medicine. As a company, we could not have accomplished what we did were it not for our commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.


DELIVERING FOR PATIENTS

Amgen is counted among the early pioneers of biologic medicines. Our therapies have since reached millions of patients worldwide. Our scientists have characterized key biologic processes that have led to the development of innovative, first-in-class therapies. We have shaped the scientific world's understanding of certain disease processes. We have also engineered new types of therapeutic platforms.

AMGEN FOUNDATION

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated more than \$250 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience, and Amgen Teach. For more information, visit www.AmgenInspires.com.



A scientist in a white lab coat is shown from the chest down, leaning over a workbench. They are using a pen to mark a gel electrophoresis image, which displays several lanes of dark spots (bands) on a light background. The entire scene is illuminated with a strong green light, creating a monochromatic effect. The scientist's face is partially visible in profile as they focus on the task.

The story of Amgen began more than three decades ago with a simple idea—that emerging research in genetics could lead to very exciting opportunities if the right scientists could be assembled and given the appropriate resources.

KEY MILESTONES

1980	Amgen is established in Thousand Oaks, California	2004	Sensipar®/Mimpara® (cinacalcet) is approved	2014	Amgen Singapore Manufacturing Pte. Ltd. construction is completed
1983	Amgen employee Fu-Kuen Lin clones erythropoietin gene	2006	Vectibix® (panitumumab) is approved		Asia Research and Development Center opened in Shanghai, China
1985	Research team at Amgen clones granulocyte colony-stimulating factor (G-CSF)	2008	Nplate® (romiplostim) is approved		BLINCYTO® (blinatumomab) is approved
1989	EPOGEN® (epoetin alfa) is approved	2010	Prolia® (denosumab) and XGEVA® (denosumab) are approved	2015	Corlanor® (ivabradine) is approved
1991	NEUPOGEN® (filgrastim) is approved	2012	deCODE Genetics, a global leader in human genetics, is acquired		Repatha® (evolocumab) is approved
2001	Aranesp® (darbepoetin alfa) is approved		Micromet, Inc., is acquired		IMLYGIC® (talimogene laherparepvec) is approved
2002	Immunex, developer of Enbrel® (etanercept), is acquired	2013	Amgen-Betta Pharmaceuticals joint venture established in China		
	Neulasta® (pegfilgrastim) is approved		Amgen Astellas BioPharma K.K. announces Japan alliance		
			Onyx Pharmaceuticals is acquired		



PRODUCTS

Aranesp® (darbepoetin alfa)	NEUPOGEN® (filgrastim)
BLINCYTO® (blinatumomab)	Nplate® (romiplostim)
Corlanor® (ivabradine)	Prolia® (denosumab)
Enbrel® (etanercept)	Repatha® (evolocumab)
EPOGEN® (epoetin alfa)	Sensipar® / Mimpara® (cinacalcet)
IMLYGIC® (talimogene laherparepvec)	Vectibix® (panitumumab)
KYPROLIS® (carfilzomib)	XGEVA® (denosumab)
Neulasta® (pegfilgrastim)	

For information about our pipeline and therapies, visit www.amgen.com.



Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

